Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | AGEN2373 |
Trade Name | |
Synonyms | AGEN-2373|AGEN 2373 |
Drug Descriptions |
AGEN2373 is a antibody that targets CD137 and acts as an agonist, resulting in increased CD137 signaling and potentially leading to enhanced anti-tumor immune response (Journal of Clinical Oncology 2019 37:15_suppl, e14005). |
DrugClasses | TNFRSF9 Antibody 32 |
CAS Registry Number | NA |
NCIT ID | C168522 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
AGEN2373 | AGEN2373 | 0 | 1 |
AGEN2373 + Balstilimab + Cyclophosphamide + GVAX | AGEN2373 Balstilimab Cyclophosphamide GVAX | 0 | 1 |
AGEN2373 + Balstilimab + Pooled Mutant KRAS-Targeted Long Peptide Vaccine | AGEN2373 Balstilimab Pooled Mutant KRAS-Targeted Long Peptide Vaccine | 0 | 1 |